RecruitingPhase 2NCT06843239
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Studying Diffuse cutaneous systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zura Bio Inc
- Principal Investigator
- Study DirectorZura Bio Inc
- Intervention
- Tibulizumab(biological)
- Enrollment
- 80 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- UCSD Altman Clinical and Translational Research Institute Center for Clinical Research, La Jolla, California, United States
- IRIS Research and Development LLC, Plantation, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Rheumatology Associates, Arlington, Texas, United States
- STAT Research S.A., Buenos Aires, Buenos Aires, Argentina
- Centro de Investigaciones Médicas Tucumán, San Miguel de Tucumán, Tucumán Province, Argentina
- Organización Médica de Investigación, Buenos Aires, Argentina
- Centro de Investigación y Prevención Cardiovascular-Arenales, Buenos Aires, Argentina
- Hospital General de Agudos Dr. José María Ramos Mejia, Buenos Aires, Argentina
- Instituto de Investigación Clínica TyT, Buenos Aires, Argentina
- Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF), Buenos Aires, Argentina
- Consultorios Médicos Dr. Doreski, Buenos Aires, Argentina
- Consultora Integral de Salud Centro Médico Privado, Córdoba, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06843239 on ClinicalTrials.govOther trials for Diffuse cutaneous systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07473154Controlling Hyperactive Immunity With Long-lived LymphocytesQuell Therapeutics Limited
- RECRUITINGPHASE1, PHASE2NCT06947473Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.Beijing GoBroad Hospital
- RECRUITINGPHASE2NCT05029336Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesStephan Grupp MD PhD
- RECRUITINGPHASE2NCT07047690A Study of Nemolizumab for the Treatment of Adults With Systemic SclerosisGalderma R&D
- RECRUITINGPHASE2NCT07287670EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Mediar Therapeutics
- RECRUITINGNCT07256418Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaCentre Hospitalier Universitaire Dijon
- RECRUITINGPHASE1NCT07295847A Study of AZD0120 in Autoimmune DiseasesAstraZeneca
- RECRUITINGNANCT07292961Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With SclerodermaHacettepe University